Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

44.15USD
17 Apr 2014
Price Change (% chg)

$0.17 (+0.39%)
Prev Close
$43.98
Open
$43.98
Day's High
$44.18
Day's Low
$43.80
Volume
105,206
Avg. Vol
213,664
52-wk High
$48.42
52-wk Low
$29.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.99
Market Cap (Mil.): $96,413.71
Shares Outstanding (Mil.): 2,212.56
Dividend: 0.83
Yield (%): 1.88

Financials

  NVO.N Industry Sector
P/E (TTM): 25.51 33.26 33.35
EPS (TTM): 1.73 -- --
ROI: 55.88 19.66 18.92
ROE: 60.54 20.35 19.68
Search Stocks

Novo Nordisk sees chance of U.S. Tresiba launch before rival products

COPENHAGEN, March 20 - Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish pharmaceutical company said on Thursday.

20 Mar 2014

BRIEF-Novo reports positive results from phase 3 trial with NovoEight

COPENHAGEN, March 19 - Danish pharmaceutical group Novo Nordisk A/S said on Wednesday: * Reports positive results from first phase 3 trial with N8-GP, a

19 Mar 2014

Novo Nordisk's IT unit appoints advisers for possible IPO

COPENHAGEN, March 18 - NNIT, the information technology unit of Danish pharmaceuticals company Novo Nordisk , said on Tuesday it had appointed Morgan Stanley and Danske Bank to advise on the possibility of a separate listing.

18 Mar 2014

UPDATE 1-NORDIC STOCKS-Factors to watch on March 6

(Adds Novo factor) The following stocks may be affected by newspaper reports and other factors on Thursday:

06 Mar 2014

Lilly weekly diabetes drug as effective as market leader Victoza-study

- An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.

25 Feb 2014

UPDATE 1-Lilly weekly diabetes drug as effective as market leader Victoza-study

Feb 25 - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.

25 Feb 2014

Lilly weekly diabetes drug succeeds vs market leader Victoza -study

Feb 25 - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.

25 Feb 2014

BRIEF-Innate Pharma buys rights to drug from Novo Nordisk

Feb 5 - Innate Pharma SA : * Buys full rights to anti-nkg2a checkpoint inhibitor from Novo Nordisk

05 Feb 2014

Israel's Oramed a step closer in race for first insulin pill

JERUSALEM - Israel's Oramed , which is racing Novo Nordisk of Denmark to develop the world's first insulin pill, moved a step closer to its goal on Thursday by announcing successful results from a small mid-stage test.

30 Jan 2014

UPDATE 1-Israel's Oramed a step closer in race for first insulin pill

* Phase IIa trial meets all primary and secondary endpoints

30 Jan 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €75.48 +0.71
Eli Lilly and Co (LLY.N) $60.43 +0.47

Earnings vs. Estimates

Search Stocks